Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women who have previously been diagnosed with invasive breast cancer or a non-invasive breast condition called DCIS
- People currently taking hormone-blocking medications called aromatase inhibitors or tamoxifen
- People who have not been using hormone replacement therapy for at least one month
- People aged 18 years or older
- People who report having hot flashes at least 14 times per week
- People who have been experiencing hot flashes for at least one month
- People taking certain antidepressants (such as venlafaxine, paroxetine, citalopram, or sertraline) or a nerve pain medication called gabapentin, provided the dose has not changed in the past 4 weeks
Who may not be able to join:
- People who have used any other hot flash treatment in the past month, including oestrogen, progesterone-type hormones, male hormones, or gabapentin
- People currently taking medications called clonidine or solifenacin (those who have stopped taking these for at least one month may be considered eligible — confirm with trial site)
- People with a history of serious kidney problems or moderate to severe liver problems
- People currently receiving or planning to receive chemotherapy or radiation therapy within the next 3 months
- People currently taking certain antidepressants known as tricyclics or MAOIs, or medications called barbiturates, or the drugs pimozide
- People currently taking a range of medications that interact with a specific liver enzyme called CYP3A4 — this includes some epilepsy, antifungal, antibiotic, and herbal medicines such as St. John's Wort, among others (confirm the full list with the trial site)
- People with poorly controlled narrow-angle glaucoma, difficulty passing urine, or problems with stomach emptying
- People with low blood pressure or poorly controlled high blood pressure
- People with serious heart or blood vessel conditions, including a heart attack within the past 3 months, a recent stroke, certain heart rhythm problems, or a history of fainting episodes
- People with a known allergy or bad reaction to clonidine or solifenacin
- People who spend more than half of their waking day in bed due to illness or limited function
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Allen C Sherman, PhD, Universitiy of Arkansas for Medical Sciences
Phone: 501-686-8700
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Efficacy: hot flash composite and frequency scores (daily diary); Safety: number of clinician-rated adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.